| 发明名称 | Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury | ||
| 摘要 | The present invention provides methods of ameliorating or reducing the extent of ischemic injury, reperfusion injury, and myocardial infarction, by administering an inhibitor of histone deacetylase enzyme (HDAC) or an inhibitor of DNA methyltransferase enzyme (DNMT). | ||
| 申请公布号 | US8889742(B2) | 申请公布日期 | 2014.11.18 |
| 申请号 | US200511791834 | 申请日期 | 2005.11.30 |
| 申请人 | The Trustees of the University of Pennsylvania | 发明人 | Gruber Peter J.;Epstein Jonathan A.;Abdullah Ibrahim |
| 分类号 | A61K31/165;A61K31/19;A61K31/185;A61K31/00 | 主分类号 | A61K31/165 |
| 代理机构 | Pearl Cohen Zedek Latzer Baratz LLP | 代理人 | Cohen Mark S.;Pearl Cohen Zedek Latzer Baratz LLP |
| 主权项 | 1. A method for reducing the size of a myocardial infarct in a subject in need thereof, the method comprising: administering to said subject a therapeutically effective amount of a histone deacetylase (HDAC) inhibitor, wherein the therapeutically effective amount of the HDAC inhibitor is administered within less than twelve hours after a myocardial infarction and wherein the HDAC inhibitor is administered orally, parenterally, intravenously, transdermally, intramuscularly or subcutaneously to said subject, thereby reducing the size of said myocardial infarct in said subject. | ||
| 地址 | Philadelphia PA US | ||